950763-33-4

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 133831-28-4 methyl 3-formyl-6-indolecarboxylate 

Downstream Products

• 950763-34-5 methyl 3-((dimethylamino)methyl)-1-(4-methoxybenzyl)-1H-indole-6-carboxylate 
• 950763-35-6 3-(4-morpholino)methylindole-1-(4-methoxybenzyl)-6-carboxylic acid methyl ester 
• 950763-36-7 3-(1-pyrrolidino)methylindole-1-(4-methoxybenzyl)-6-carboxylic acid methyl ester 
• 950763-37-8 3-(N-benzylamino)methylindole-1-(4-methoxybenzyl)-6-carboxylic acid methyl ester 
• 950763-10-7 3-(4-morpholino)methylindole-l-(4-methoxybenzyl)-6-carboxylic acid hydroxyamide 
• 950763-13-0 3-(N-pyrrolidinomethyl)-1-(4-methoxybenzyl)-1H-indole-6-carboxylic acid hydroxyamide 
• 950763-16-3 3-(N-benzylaminomethyl)-1-(4-methoxybenzyl)-1H-indole-6-carboxylic acid hydroxyamide 
• 950763-07-2 3-((dimethylamino)methyl)-N-hydroxy-1-(4-methoxybenzyl)-1H-indole-6-carboxamide 

Relevant academic research and scientific papers

Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors

We report the synthesis and evaluation of a class of selective multitarget agents for the inhibition of HDAC6, HDAC8, and HDAC10. The concept for this study grew out of a structural analysis of the two selective inhibitors Tubastatin A (HDAC6/10) and PCI-

INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the acitivy of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.